PHATHOM PHARMACEUTICALS INC

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical company whose drug development pipeline requires animal testing as part of the preclinical research and regulatory submission process. The company’s SEC filings routinely cite the completion of animal studies as a standard step toward advancing its investigational compounds, including its approved product VOQUEZNA® (vonoprazan). FDA approval documents for vonoprazan reference findings from required animal studies that are described in the product’s official labeling.

As a pharmaceutical company seeking regulatory approval for new chemical entities, Phathom funds and commissions animal testing to satisfy preclinical safety and efficacy requirements, a practice inherent to its business model. This places the company within the scope of the exclusion for animal testing, which applies to firms that test on animals as part of product development or regulatory compliance, regardless of whether the testing is conducted in-house or outsourced.